Adults coming off GLP-1 drugs who got a wellness app or medically tailored meals regained about 7% less weight than usual care, in a small trial of 39 people.
Recap by typeshit. Full story at MPR.
U of T researchers built the AI tool with the aim of speeding up how new peptide drugs are found. The university's announcement has the details.
Fractyl plans to file a De Novo request with the FDA in late Q4, yet its shares closed about 63% lower that day over a class action and doubts about 12-month results.
Health records from 131 million adults linked GLP-1s to fewer dialysis or transplant cases. The researchers stress the study is observational and can't prove cause.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
In a JAMA Network Open study of 3,615 adults, GLP-1 use was 20.5% among cancer survivors versus 26.5% in those without cancer, even though survivors carried more heart and kidney risk.
Three posters on November 14 and 15 compare the preclinical pill with orforglipron in animal models. Rivus says it plans to file an IND in Q1 2027.
Loading…